KRBP Kiromic BioPharma Inc.

FDA Catalyst Company
0.35
+0.01  (+4%)
Previous Close 0.33
Open 0.33
52 Week Low 0.2993
52 Week High 11
Market Cap $5,462,690
Shares 15,751,701
Float 15,241,985
Enterprise Value $-18,519,962
Volume 196,151
Av. Daily Volume 212,866
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Latest News

  1. Recent Corporate Highlights Include:

    • New Leadership Appointed at the Company, Board of Director Level
    • Completed Studies to Further Optimize Potency and Validity of the ALEXIS Gamma Delta T (GDT) Cell Platform
    • Progressed a Master Cell Bank Strategy for Retro-viral Vector (RVV) Production
    • Enhanced Kiromic's Diamond AI™ Mediated Pooled Donor Gamma Delta T Cell Banking Technology
    • Expansion and Redesign of In-house cGMP Manufacturing Facility
    • DIAMOND®AI 2.0 New Component NOEMI (NeurO Evolutive) Machine Learning Enabled Antibody Design) Designed to Dramatically Reduce Time and Cost of CAR-T Cell Therapy Development
    • Cash Position $15,123,100 as of March 31, 2022

    Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company")

    View Full Article
  2. Company Provides Regulatory Update on Progress to Address Previously Outlined Chemistry, Manufacturing, and Control (CMC) Issues Related to Clinical Hold on Investigational New Drug Applications (INDs)

    A Type A FDA Meeting Will Not Be Pursued

    Company Announces Ongoing Progress Towards the Implementation by the Beginning of the Third Quarter of 2022 of a Current Good Manufacturing Practice (cGMP) Mammalian Master Cell Bank (mMCB), a Key Component to Manufacture a GMP-Grade Retroviral Vector for Gamma Delta T (GDT) Cell Engineering

    Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform…

    View Full Article
  3. Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND AI® (artificial intelligence) and big data mining platform to discover, validate and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces the availability of the Company's most recent corporate presentation. The updated presentation can be accessed on the investor relations section of the Company's website. The corporate presentation was also filed as a Form 8-K with the Securities and Exchange Commission. See the updated corporate presentation here Kiromic BioPharma April 2022 Corporate Presentation.

    About Kiromic BioPharma

    Kiromic BioPharma, Inc…

    View Full Article
  4. Highlights Include Company's Progress in the Following Areas:

    • Advances in the Research, Development, and Manufacturing Processes of the ALEXIS Gamma Delta T cell Platform
    • Key Hires in Research & Development, Clinical Translational Medicine and Clinical Trial Preparation
    • Completion of Approximately 90% of In-house cGMP Facility Expansion and Redesign
    • Launch of DIAMOND® Artificial Intelligence (AI) 2.0 Platform for Identification and Selection of Immunotherapy Targets, which Now Includes Nearly Two Billion Data Points

    Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform…

    View Full Article
  5. Company Expects to File 2021 Form 10-K Prior to 15-day Extension Period Expiration

    Kiromic BioPharma, Inc. (NASDAQ:KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and big data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases, today announces that it has filed a Form 12b-25 with the SEC to obtain a 15-calendar day extension to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the "2021 Form 10-K"). The Company expects to file its 2021 Form 10-K during the 15-calendar day extension period.

    About Kiromic BioPharma

    Kiromic BioPharma…

    View Full Article
View All Kiromic BioPharma Inc. News